Document:

Exhibit 10.9

 

 

OPTION AGREEMENT

 

This Option
Agreement evidences the grant of a stock option (the "Option") to purchase shares of common stock, par value $.001 (the
"Company Stock"), of Generex Biotechnology Corporation (the "Company") granted to John Barratt
(the "Optionee") pursuant to the Generex Biotechnology Corporation Amended
2001 Stock Option Plan (the “Plan”), a copy of which is attached to this Option Agreement and incorporated into this
Option Agreement by reference. The Option is subject to the terms, conditions, limitations and restrictions set forth in the Plan,
including the following:

 

a.The date of grant
of the Option is October 31, 2013, and the number of shares of Company Stock that may be purchased upon exercise of the
Option is 400,000.

 

b.The purchase price
(the “Exercise Price”) of Company Stock subject to the Option is $0.001 per share.

 

c.The
Option shall become exercisable as follows, subject to the terms, conditions, limitations and restrictions set forth in the Plan:
400,000 shares will vest on January 1, 2014. Only options
that have vested may be exercised.

 

d.Unless sooner terminated
pursuant to the Plan, the Option shall terminate on October 31, 2018.

 

e.The Optionee shall
pay the Exercise Price for the Option (i) in cash or (ii) by such other method as may be approved by the Compensation Committee
of the Company’s Board of Directors. The Optionee shall pay the amount of any withholding tax due at the time of exercise,
as provided in the Plan.

 

f.The rights and interests
of the Optionee under this Option Agreement may not be sold, assigned, encumbered or otherwise transferred, except, in the event
of the death of the Optionee, by will or by the laws of descent and distribution.

 

g.Any notice to the
Company, including notice of exercise of an Option, shall be addressed to the Company in care of Mark Fletcher at the Company’s
principal offices.

 

IN
WITNESS WHEREOF, this Option Agreement has been executed on behalf of the Company by a duly authorized officer and by the Optionee
effective as of the date of grant of the Option.

 

 

	GENEREX BIOTECHNOLOGY CORPORATION	 	ACCEPTED AND AGREED:
	 	 	 	 
	 	 	 	 
	Per:	/s/ Mark Fletcher	 	/s/
John Barratt
	Name:	Mark A. Fletcher,	 	John Barratt, Optionee
	 	President & CEO	 	 
	 	 	 	 
	Per:	/s/ Stephen Fellows	 	 
	Name:	Stephen Fellows,	 	 
	 	Chief Financial OfficerExhibit 10.10

 

 

OPTION AGREEMENT

 

This Option
Agreement evidences the grant of a stock option (the "Option") to purchase shares of common stock, par value $.001 (the
"Company Stock"), of Generex Biotechnology Corporation (the "Company") granted to David Brusegard
(the "Optionee") pursuant to the Generex Biotechnology Corporation Amended 2001 Stock Option Plan (the “Plan”),
a copy of which is attached to this Option Agreement and incorporated into this Option Agreement by reference. The Option is subject
to the terms, conditions, limitations and restrictions set forth in the Plan, including the following:

 

a.The date of grant
of the Option is October 31, 2013, and the number of shares of Company Stock that may be purchased upon exercise of the
Option is 400,000.

 

b.The purchase price
(the “Exercise Price”) of Company Stock subject to the Option is $0.001 per share.

 

c.The
Option shall become exercisable as follows, subject to the terms, conditions, limitations and restrictions set forth in the Plan:
400,000 shares will vest on January 1, 2014. Only options
that have vested may be exercised.

 

d.Unless sooner terminated
pursuant to the Plan, the Option shall terminate on October 31, 2018.

 

e.The Optionee shall
pay the Exercise Price for the Option (i) in cash or (ii) by such other method as may be approved by the Compensation Committee
of the Company’s Board of Directors. The Optionee shall pay the amount of any withholding tax due at the time of exercise,
as provided in the Plan.

 

f.The rights and interests
of the Optionee under this Option Agreement may not be sold, assigned, encumbered or otherwise transferred, except, in the event
of the death of the Optionee, by will or by the laws of descent and distribution.

 

g.Any notice to the
Company, including notice of exercise of an Option, shall be addressed to the Company in care of Mark Fletcher at the Company’s
principal offices.

 

IN
WITNESS WHEREOF, this Option Agreement has been executed on behalf of the Company by a duly authorized officer and by the Optionee
effective as of the date of grant of the Option.

 

 

	GENEREX BIOTECHNOLOGY CORPORATION	 	ACCEPTED AND AGREED:
	 	 	 	 
	 	 	 	 
	Per:	/s/ Mark Fletcher	 	/s/
David Brusegard
	Name:	Mark A. Fletcher,	 	David Brusegard, Optionee
	 	President & CEO	 	 
	 	 	 	 
	Per:	/s/ Stephen Fellows	 	 
	Name:	Stephen Fellows,	 	 
	 	Chief Financial OfficerExhibit 10.11

 

 

OPTION AGREEMENT

 

This Option
Agreement evidences the grant of a stock option (the "Option") to purchase shares of common stock, par value $.001 (the
"Company Stock"), of Generex Biotechnology Corporation (the "Company") granted to Stephen Fellows (the
"Optionee") pursuant to the Generex Biotechnology Corporation Amended 2001 Stock Option Plan (the “Plan”),
a copy of which is attached to this Option Agreement and incorporated into this Option Agreement by reference. The Option is subject
to the terms, conditions, limitations and restrictions set forth in the Plan, including the following:

 

a.The date of grant
of the Option is October 31, 2013, and the number of shares of Company Stock that may be purchased upon exercise of the
Option is 400,000.

 

b.The purchase price
(the “Exercise Price”) of Company Stock subject to the Option is $0.001 per share.

 

c.The
Option shall become exercisable as follows, subject to the terms, conditions, limitations and restrictions set forth in the Plan:
400,000 shares will vest on January 1, 2014. Only options
that have vested may be exercised.

 

d.Unless sooner terminated
pursuant to the Plan, the Option shall terminate on October 31, 2018.

 

e.The Optionee shall
pay the Exercise Price for the Option (i) in cash or (ii) by such other method as may be approved by the Compensation Committee
of the Company’s Board of Directors. The Optionee shall pay the amount of any withholding tax due at the time of exercise,
as provided in the Plan.

 

f.The rights and interests
of the Optionee under this Option Agreement may not be sold, assigned, encumbered or otherwise transferred, except, in the event
of the death of the Optionee, by will or by the laws of descent and distribution.

 

g.Any notice to the
Company, including notice of exercise of an Option, shall be addressed to the Company in care of Mark Fletcher at the Company’s
principal offices.

 

IN
WITNESS WHEREOF, this Option Agreement has been executed on behalf of the Company by a duly authorized officer and by the Optionee
effective as of the date of grant of the Option.

 

 

 

	GENEREX BIOTECHNOLOGY CORPORATION	 	ACCEPTED AND AGREED:
	 	 	 	 
	 	 	 	 
	Per:	/s/ Mark Fletcher	 	/s/
Stephen Fellows
	Name:	Mark A. Fletcher,	 	Stephen Fellows, Optionee
	 	President & CEO	 	 
	 	 	 	 
	Per:	/s/ Stephen Fellows	 	 
	Name:	Stephen Fellows,	 	 
	 	Chief Financial OfficerExhibit 10.12

 

 

OPTION AGREEMENT

 

This Option
Agreement evidences the grant of a stock option (the "Option") to purchase shares of common stock, par value $.001 (the
"Company Stock"), of Generex Biotechnology Corporation (the "Company") granted to Mark Fletcher (the
"Optionee") pursuant to the Generex Biotechnology Corporation Amended 2001 Stock Option Plan (the “Plan”),
a copy of which is attached to this Option Agreement and incorporated into this Option Agreement by reference. The Option is subject
to the terms, conditions, limitations and restrictions set forth in the Plan, including the following:

 

a.The date of grant
of the Option is October 31, 2013, and the number of shares of Company Stock that may be purchased upon exercise of the
Option is 400,000.

 

b.The purchase price
(the “Exercise Price”) of Company Stock subject to the Option is $0.001 per share.

 

c.The
Option shall become exercisable as follows, subject to the terms, conditions, limitations and restrictions set forth in the Plan:
400,000 shares will vest on January 1, 2014. Only options
that have vested may be exercised.

 

d.Unless sooner terminated
pursuant to the Plan, the Option shall terminate on October 31, 2018.

 

e.The Optionee shall
pay the Exercise Price for the Option (i) in cash or (ii) by such other method as may be approved by the Compensation Committee
of the Company’s Board of Directors. The Optionee shall pay the amount of any withholding tax due at the time of exercise,
as provided in the Plan.

 

f.The rights and interests
of the Optionee under this Option Agreement may not be sold, assigned, encumbered or otherwise transferred, except, in the event
of the death of the Optionee, by will or by the laws of descent and distribution.

 

g.Any notice to the
Company, including notice of exercise of an Option, shall be addressed to the Company in care of Mark Fletcher at the Company’s
principal offices.

 

IN
WITNESS WHEREOF, this Option Agreement has been executed on behalf of the Company by a duly authorized officer and by the Optionee
effective as of the date of grant of the Option.

 

 

	GENEREX BIOTECHNOLOGY CORPORATION	 	ACCEPTED AND AGREED:
	 	 	 	 
	 	 	 	 
	Per:	/s/ Mark Fletcher	 	/s/
Mark Fletcher
	Name:	Mark A. Fletcher,	 	Mark Fletcher, Optionee
	 	President & CEO	 	 
	 	 	 	 
	Per:	/s/ Stephen Fellows	 	 
	Name:	Stephen Fellows,	 	 
	 	Chief Financial OfficerExhibit 10.13

 

 

OPTION AGREEMENT

 

This Option
Agreement evidences the grant of a stock option (the "Option") to purchase shares of common stock, par value $.001 (the
"Company Stock"), of Generex Biotechnology Corporation (the "Company") granted to Brian McGee
(the "Optionee") pursuant to the Generex Biotechnology Corporation Amended 2001 Stock Option Plan (the “Plan”),
a copy of which is attached to this Option Agreement and incorporated into this Option Agreement by reference. The Option is subject
to the terms, conditions, limitations and restrictions set forth in the Plan, including the following:

 

a.The date of grant
of the Option is October 31, 2013, and the number of shares of Company Stock that may be purchased upon exercise of the
Option is 400,000.

 

b.The purchase price
(the “Exercise Price”) of Company Stock subject to the Option is $0.001 per share.

 

c.The
Option shall become exercisable as follows, subject to the terms, conditions, limitations and restrictions set forth in the Plan:
400,000 shares will vest on January 1, 2014. Only options
that have vested may be exercised.

 

d.Unless sooner terminated
pursuant to the Plan, the Option shall terminate on October 31, 2018.

 

e.The Optionee shall
pay the Exercise Price for the Option (i) in cash or (ii) by such other method as may be approved by the Compensation Committee
of the Company’s Board of Directors. The Optionee shall pay the amount of any withholding tax due at the time of exercise,
as provided in the Plan.

 

f.The rights and interests
of the Optionee under this Option Agreement may not be sold, assigned, encumbered or otherwise transferred, except, in the event
of the death of the Optionee, by will or by the laws of descent and distribution.

 

g.Any notice to the
Company, including notice of exercise of an Option, shall be addressed to the Company in care of Mark Fletcher at the Company’s
principal offices.

 

IN
WITNESS WHEREOF, this Option Agreement has been executed on behalf of the Company by a duly authorized officer and by the Optionee
effective as of the date of grant of the Option.

 

 

	GENEREX BIOTECHNOLOGY CORPORATION	 	ACCEPTED AND AGREED:
	 	 	 	 
	 	 	 	 
	Per:	/s/ Mark Fletcher	 	/s/
Brian McGee
	Name:	Mark A. Fletcher,	 	Brian McGee, Optionee
	 	President & CEO	 	 
	 	 	 	 
	Per:	/s/ Stephen Fellows	 	 
	Name:	Stephen Fellows,	 	 
	 	Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]